Xenetic Biosciences, Inc. (NASDAQ:XBIO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02 Departure of Directors or Principal Officers; Election
of Directors; Appointment of Principal Officers

On January 1, 2017, our Board of Directors appointed Dr. Curtis
Lockshin to the position of Chief Scientific Officer (CSO). Dr.
Lockshin is a Ph.D. in Biological Chemistry (Massachusetts
Institute of Technology 1998), who has held management positions
in development and commercial stage biotechnology companies, with
experience including discovery, preclinical and clinical
development, as well as commercial manufacturing. Over the past
five years, Dr. Lockshin has worked as an officer or consultant
of several biotechnology companies, including: (a) from March
2014 to December 2016 as the Vice President of Research
Operations of our company; (b) since May 2013 as
President and CEO of Guardum Pharmaceuticals LLC; (c) from
September 2014 to December 2016 as an officer of a series of
related companies following multiple mergers beginning as CEO of
SciVac Ltd (Sept 2014-July 2015), CEO of SciVac Therapeutics Inc.
(July 2015-May 2016), and CTO of VBI Vaccines Inc. (May 2016-
December 2016); (d) from October 2011 to February 2013 as Vice
President of Corporate RD Initiatives for OPKO Health. Dr.
Lockshin is also a member of the board of directors of RXi
Pharmaceuticals (RXII) (Since April 2013), and has been a
director of Chromadex Inc (CDXC) (March 2011 – December 2013) and
Sorrento Therapeutics (SRNE) (October 2009 September 2012).

There are no family relationships between Mr. Lockshin and any of
our current directors or executive officers. Mr. Lockshin has not
had any material direct or indirect interest in any of our
transactions or proposed transactions over the last two years. A
copy of Mr. Lockshin s employment agreement, approved by the
Board of Directors, is attached hereto as Exhibit 10.1.

SECTION 7 Regulation FD

Item 7.01 Regulation FD Disclosure

In addition to disclosing current information to Section 13 or
15(d) of the Securities Exchange Act of 1934 and for reports of
information required to be disclosed by Regulation FD through our
SEC filings, we also intend to disclose such current information
through our investor relations website, press releases, public
conference calls, webcasts and through the following social media
channels:

(https://plus.google.com/103621858654196899741/about)

(http://www.thechairmansblog.com/xenetic-biosciences)

SECTION 8 OTHER EVENTS

Item 8.01 Other Events

On January 4, 2017, we issued a press release announcing the
appointment of Curtis Lockshin as the Companys new Chief
Scientific Officer. A copy of the Press Release is attached
hereto as Exhibit 99.1.

SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS

Item 9.01 Financial Statement and Exhibits

About Xenetic Biosciences, Inc. (NASDAQ:XBIO)

Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company’s technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company’s lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.

Xenetic Biosciences, Inc. (NASDAQ:XBIO) Recent Trading Information

Xenetic Biosciences, Inc. (NASDAQ:XBIO) closed its last trading session down -0.04 at 4.83 with 71,153 shares trading hands.